#MedCase - 3 months after starting secukinumab for psoriasis and ankylosing spondylitis, a patient developed chronic diarrhea.
Investigation revealed #CrohnsDisease, which resolved after the IL-17A inhibitor was discontinued.
👉️ buff.ly/czsoXzP
#MedSky
Three months after starting secukinumab for psoriasis and ankylosing spondylitis, a patient developed chronic diarrhea. Investigation revealed Crohn's disease, which resolved after the IL-17A…